Human papillomavirus (HPV) is a known risk factor for certain head and neck cancers. 18 Tumors of head and neck region are heterogeneous in nature with different incidences, mortalities 19 and prognosis for different subsites. Unlike oropharynx, where data favors inclusion of HPV status 20 in disease management, role of HPV in oral cavity squamous cell carcinoma (OSCC) is not well 21 understood. The prevalence of HPV in OSCC, although considered lower than oropharynx, vary 22 greatly based on the choice of HPV assay and patient geography. Additionally, data on HPV +ve 23 OSCC is scarce and there is less agreement on HPV being a good prognostic factor in OSCC. Here 24 with 153 OSCC patients, using multiple analytes and assays, we show that a high prevalence (33-25 58%) of HPV16/18 DNA did not correlate with an equally high prevalence of transcriptionally 26 active viral genomes (E6/E7 RNA prevalence 15%) in tumors. Only 6% of the tumors showed the 27 presence of both HPV DNA and HPV16/18 E6/E7 RNA and none with both p16 and HPV RNA. 28 Most tumors with relatively high-copy HPV DNA and/or HPV E6/E7 mRMA, but not with HPV 29 DNA alone (irrespective of copy number), were wild type for TP53 and CASP8 genes. In our study, 30 p16 protein, HPV DNA and E6/E7 RNA, either alone or in combinations, did not correlate with 31 patient survival. Using genome-wide methylation data, 9 HPV-associated genes stratified the HPV 32 +ve from the HPV -ve tumor groups with high confidence (p<0.008) when relatively high-copy 33 number of HPV DNA and/or HPV E6/E7 RNA were considered to define HPV positivity and not 34 HPV DNA alone irrespective of their copy number (p<0.2). Taken together, we conclude that tests 35 measuring HPV DNA alone without viral load and/or viral RNA may not be a true measures of 36 HPV infection in oral cavity tumors and therefore are not informative. 37 38 39 methylation. 40 41 42 43 48 with human papillomavirus (HPV) [3]. Unlike oropharyngeal tumors, where the HPV incidence is 49 reported to be very high, (upto 90%) [4,5], the incidence of HPV in OSCC varies widely (from 50 none to 74%) depending on the detection methodology used and the geography of the patient cohort 51 [6]. Additionally, unlike oropharngeal tumors [7-11], the role of HPV in disease prognosis and 52 response to therapy in patients with OSCC is less equivocal. Among the high risk HPV types, 53 infection with HPV16 or HPV18 has been epidemiologically linked with head and neck 54 malignancies [12]. Presennce of HPV DNA is routinely used as a measure of HPV infection in 55 tumors. However, there is a considerable variation in the sensitivity of DNA-based assays, which 56 leads to differences in reporting HPV DNA prevalence among different cohorts. On the otherhand, 57 the presence of HPV E6/E7 RNA and/or their associated protein products remain as gold standard 58 tests defining HPV positivity. 59 60 Large-scale sequencing studies have demonstrated that the majority of HPV-negative 61 tumors harbor mutations in TP53 and CASP8 and a large proportion of HPV-positive tumors in 62 PIK3CA [13-15]. Additionally, past studies have identified specific mutations in potential drug 63 targets like FGFR2/3 and lack of EGFR abberations in HPV-positive patients [15] and the role of 64 CASP8 in HPV-negative cell line and patients [13,16]. Despite the wealth of information, which 65 HPV tests are accurate and whether HPV plays an important factor in oral cavity tumor 66 stratification and treatment remain to be answered. 67 68 In the present study, we addressed the following questions on HPV in a cohrt of 153 patients 69 with oral cavity tumors. Does sensitivity matter in the detection of HPV DNA in tumors? Does 70 presence of tumor p16 and HPV DNA correlate with that of HPV E6/E7 RNA? Is high-copy HPV 71 DNA a true refelction of HPV infection in oral cavity tumors? Are p16 protein, HPV DNA, HPV 72 E6/E7 RNA, individually or together, linked with patient survival? And finally, do somatic 73 mutations and gene methylation at 5-Cytosine residues distinguish the HPV +ve from the HPV -ve 74 tumors? 75 76 Materials and Methods 77 Patient cohort 78
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 45 worldwide with an incidence of 550,000 cases annually [1] . Oral cavity squamous cell carcinoma 46 (OSCC) constitute a majority of HNSCC including tumors of oral/anterior tongue and buccal mucosa [2] . The major known risk factors of OSCC are tobacco products, alcohol, and infection solution and 1X penicillin/streptomycin mixture (Gibco) and grown in incubators at 37 0 C with 5% 97 CO 2 . 98 99 Immunohistochemistry (IHC) 100 For p16 immunohistochemistry (IHC) staining was carried out using primary antibody from For qPCR, E6 and E7 regions from HPV16 and HPV18 respectively were cloned in pUC19 123 vector. The sequences for the recombinant plasmids were confirmed by Sanger sequencing. The 124 qPCR was carried out using KAPA Probe Fast qPCR master mix Universal (2X) (cat: KK4701, 125 KAPA Biosystems, USA). The primers and probes were designed ( Supplementary Table 2 ) within 126 the cloned regions of the HPV16 and HPV18 plasmids and standard quantitative PCR was 127 performed. The standard curves were generated using serial dilutions (from 10 to 100,000 copies) of 128 HPV16 and HPV18 cloned pUC19 plasmids. Genomic DNA from postive and negative control cell 129 lines wers used as positive and negative controls for HPV18 and HPV16 respectively 130 ( Supplementary Figure 1) . All amplification reactions were carried out in triplicates, using nuclease 131 free water (cat: AM9932, Ambion, USA) as negative control. The analysis for each sample was 132 done by using the absolute quantification using standard curve generated with serial dilutions of 133 cloned plasmids. Tumors and cell lines samples were counted as positive for those having Ct values 134 3 times away from the standard deviation from the negative controls. 135 136 Detection of HPV DNA using droplet digital PCR (ddPCR) 137 Digital PCR was performed using the QX100 droplet digital PCR system (Bio-Rad, USA) 138 using primers and probes as provided in Supplementary Table 2 . The reaction mix consisted of 139 10 μl of 2× ddPCR Supermix without dUTP (cat: 1863024; Bio-Rad, USA), 450 nM of both 140 forward and reverse primers of HPV16 and 250 nM probe and 300ng of genomic DNA in a final 141 volume of 20 μl. The entire 20 μl reaction was loaded into a droplet cartridge, followed by 70 μl of 142 droplet generation oil and droplets were generated using droplet generator. The droplets were 143 transferred into a 96-well PCR plate (PCR96-FLT-C, Axygen, USA) and sealed using an 144 aluminium foil. Further, the PCR amplification was carried out on in a thermal cycler (C1000, Rad, USA). After amplification, the plate was transferred to a Bio-Rad droplet reader. The droplets 146 per well were measured and normalized in every reaction using the Quantasoft V.6 software Rad, USA). All the samples were processed in triplicates. Tumors and cell lines samples were counted as positive for those having droplet numbers 3 times away from the standard deviation 149 from the negative controls. 150 151 HPV DNA copy number 152 We deduced the HPV absolute copy number from the qPCR standard curves using cloned 153 HPV16/18 (Figure 2A,D) . We considered a tumor or cell line to have relatively high-copy of HPV 154 DNA when the copy number for HPV16 and HPV18 DNA were more than 3.3 x 10 2 and 3.3 x 10 3 155 per microgram of tumor DNA respectively. In order to minimize the effect of tumor cellularity, 156 ploidy and heterogeneity, we expressed the HPV copy number as copies per microgram of tumor 157 DNA used in the reaction. 
Integration status of HPV genome
We performed HPV16E2 PCR [21, 22] to determine whether HPV has integrated into tumor 176 genomes or remained as episomal DNA in tumors those were positive for HPV DNA and RNA. 177 Genomic DNA from the early passage of W12 cell line (gift from Prof. Sharmila Sengupta, 178 NIBMG, Kalyani, India) and p3796 pGEX-16E2 (wt) (Addgene plasmid # 24123) were used as 179 positive controls for E2 PCR. In addition, genomic DNA from UPCI;SCC29B and PCI:SCC040 180 cell lines were used as negative controls. The primer sequences and the amplification conditions are 181 provided in Supplementary Table 2 BeadChip, chip scanning and the data pre-processing are described previously [23] . Three tumors in from -1 (hypo-methylation) to 1 (hyper-methylation). Using a supervised clustering approach, differentially methylated probes that discriminated HPV +ve and HPV -ve patients samples were 203 identified. Hyper-methylated probes in the HPV +ve group that were hypo-methylated in the HPV -204 ve group, and vice versa, along with other probes with Δβ values that differed by at least 0.5 205 between the two groups, with a sample frequency of at least 60% were considered further. Finally, 206 the list of genes consisting of average Δβ values across tumors for multiple probes (where present) 207 was drawn. Neighborhood interaction network for these genes was inferred using PCViz from 208 PathwayCommons (http://www.pathwaycommons.org/pcviz/#neighborhood/). The genes and their 209 interacting partners were mapped to the Viral Carcinogenesis pathway from KEGG (hsa05203), and 210 mapped genes were linked back to respective genes found using supervised clustering. For the 211 linked genes, an unpaired t-test was performed to determine the significance of difference between 212 the HPV +ve and HPV -ve tumor groups. The same was performed for the HPV-associated genes 213 between the DNA-based (irrespective of the DNA copy number) HPV +ve and HPV -ve tumor 214 groups.
216
Results 217 p16 expression 218 The tumors (n = 56) were first confirmed by H and E staining of the paraffin tissue sections 219 followed by the immunohistochemical staining with the surrogate marker p16. Supplementary 220 Figure 2 shows the representative p16 +ve and -ve staining in oral cavity tumor sections (OSCC) 221 along with the cervical tissue section (+ve control). Fifty one percent (28/55) of the oral cavity 222 tumors studied showed positive p16 staining ( Table 1) .
224
Incidence of HPV DNA 225 We used three different molecular techniques (PCR, quantitative PCR and digital PCR) to 226 detect HPV DNA in oral cavity tumors. We tested 5 sets of primers published in the literature and 2 227 newly designed ones in the amplification reactions ( Figure 1A) . The primers were either consensus 228 (GP5 + 6 + , MY09/11, CPI-II and PGMY09/11) or type-specific (HPV16L1, HPV16E6 and HPV18L1). We used genomic DNA from UMSCC-47 and Hep2 cell lines to detect HPV16 and 230 HPV18 respectively at various dilutions to determine relative efficiency, sensitivity and accuracy of 231 amplification ( Figure 1B ). Primers described in the literature (GP5 + 6 + , MY09/11, CPI-II or 232 PGMY09/11, HPV16L1) could only detect HPV DNA when 0.03ng or higher amount of genomic 233 DNA from the cell line UMSCC-47/Hep2 was used ( Figure 1B) . However, the newly designed type 234 specific primers (HPV16E6 and HPV18L1) were able to detect HPV DNA with as low as 0.0003ng 235 and 0.003ng genomic DNA for HPV16 and HPV18 respectively ( Figure 1B) . In order to check the 236 efficiency of the newly designed primers in relation to absolute copy numbers of HPV genome, we 237 used serial diluted HPV cloned plasmids DNA. As shown in Supplementary Figure 3 , efficient 238 amplification with 100 copies of HPV genome or higher could be detected. Once we optimized the 239 conditions and primers for all the amplification reactions, we performed PCR in oral cavity tumors 240 (n = 70). In our cohort, 58% (41/70) of the tumors were HPV DNA +ve for any of the PCR (Table   241 1, Supplementary Figure 4 ). Figure 1C shows the efficiency of the consensus and type specific Next, we used quantitative PCR using Taqman chemistry to detect HPV DNA. We 252 performed serial dilution using HPV16 E6 and HPV18 L1 cloned plasmids to obtain standard 253 curves (Figure 2 A,D). We used increasing amount of genomic DNA from negative control cell 254 lines to demonstrate specific amplification of HPV DNA ( Supplementary Figure 1) . Genomic DNA 255 from HPV +ve and -ve cell lines were used to plot the baseline. Tumors were counted as HPV DNA positive for those having Ct values 3 times away from the standard deviation from the 257 negative controls (Figure 2 B,E). Results from qPCR indicated that 33% (35/106) of tumors were 258 positive for HPV DNA (Table 1) . Although, we found high incidence for HPV16 (30%; 32/106) 259 than HPV18 (18%; 19/106) type, the HPV18 positive tumors had very high copy numbers of viral 260 DNA as refelcted in their Ct values (Figure 2 C,F). The prevalence of HPV DNA in oral tongue 261 tumors was higher (44%) compared to that of buccal mucosa (4%).
263
Finally, we used one of the most sensitive methods, digital PCR, to detect HPV DNA. 264 Digital PCR is recently shown succefully to detect HPV DNA in oropharyngeal tumors in highly 265 specific manner [24] . We performed droplet digital PCR (ddPCR) with serially diluted plasmid 266 HPV16E6 clones to generate the standard curve ( Figure 2G ). The genomic DNA from positive-267 (UM-SCC47) and negative control cell lines (Hep2) for HPV16 along with a no template control 268 (NTC) were used to plot the baseline ( Figure 2H ). Digital PCR results indicated that 43% (59/136) 269 of oral cavity tumors were positive for HPV16 DNA (Table 1) . Moreover, HPV16 infection was 270 more prevalent in oral tongue tumors (55%) compared to buccal mucosal ones (17%) ( Table 1) . (Table 1) . Similar to DNA, oral tongue tumors had higher number (17%) of HPV E6/E7 RNA 279 compared to the buccal mucosa (9%, Table 1 ). In our cohort, younger patients (≤40yrs age) were 280 significantly more HPV RNA +ve than the older patients when analyzed by Chi-square analysis (p 281 = 0.029).
When combining the results from all the assays (p16 IHC, HPV DNA and HPV RNA), we 283 found 0-48% of the tumors were positive in various assay combinations with PCR + ddPCR 284 yielding the highest (48%) and p16 IHC + RNA the lowest (0%) numbers (Table 1) . We found that 285 22% (23/106) of the tumors had relatively high-copy of HPV DNA and/or HPV E6/E7 mRNA.
287
Integration of HPV DNA in the host tumor genomes 288 We performed HPV16 E2 PCR to understand what percent of HPV DNA is integrated into 289 the host tumor genomes and found that HPV is episomal in 18 % (n = 40) of the oral cavity tumors 290 and in the majority of cases, HPV DNA was integrated into the host genome ( Table 1) Supplementary Figure 9 I, p=0.03 ). We found no correlation between HPV E6/E7 mRNA and with 304 both overall (p=0.7) and disease-free (p=0.3) survival ( Supplementary Figure 9 M,N) . 305 306 Furhter, we investigated whether somatic mutations in significantly mutated genes in OSCC 307 have a role to play in HPV DNA +ve tumors and patient survival. We looked at 3 genes (TP53, 308 CASP8, RASA1) shown to be significantly mutated in oral cavity tumors [13, 16, 25] and tested whether the mutation in any of the genes, alone or in combination, with relatively high HPV DNA 310 copy and/or HPV E6/E7 mRNA is linked with survival. As shown in Figure 4A , we did not find any 311 significant association with this group of tumors with both overall-(p = 0.45) and disease-free (p = 312 0.68) survival. Ninty five percent of the HPV +ve tumors in the group were wild-type for TP53, and 313 CASP1 gene and 85% of the HPV +ve tumors for RASA1. (Figure 4B ). Somatic mutations in a 314 group with relatively high-copy of HPV DNA, either alone or in combinations, were not associated 315 with both overall and disease-free survival ( Supplementary Figure 10 (Figure 4C ). All the genes, except for HOXA2, were significantly 325 hypermethylated in the HPV +ve group of tumors compared to the HPV -ve group ( Figure 4C ). The 326 linked 4 genes, obtained from the 9 significantly methylated genes, were mapped to the pathways 327 involving HPV E6 and E7 proteins ( Figure 4D ). To test significance, we performed unpaired t-tests 328 between the two groups, group 1 that has relatively high-copy HPV DNA and/or HPV RNA and 329 group 2 that were negative for both HPV DNA and HPV RNA. All of the 8 hypermethylated genes 330 showed very significance (p < 0.00001) and for HOXA2 that was hypomethylated the p-value was 331 0.007. However, when the patients were grouped based on HPV DNA positivity alone (irrespective 332 of their copy number), most of these 9 HPV-linked genes did not show significant association 333 ( Supplementary Table 3 ).
334

Discussion
336
HPV plays an important role in the prognosis of patients with oropharyngeal tumors [26, 27] . 337 Unlike oropharynx, HPV incidence and its role in disease prognosis in oral cavity tumors is not well 338 established. Past results on HPV DNA incidence in oral cavity tumors were widely variable (from 339 very low to very high) depending on the assay sensitivity, analyte and patient cohort used [28] . The 340 accuracy of the HPV tests employed is important and HPV positivity need to be answered in order 341 to make treatment decisions in patients with head and neck tumors confidently [29] . There are fewer 342 studies that used multiple analytes (protein, DNA and RNA) and multiple molecular tests (IHC, 343 PCR, qPCR and digital PCR) to establish HPV positivity in oral cavity tumors and that correlated 344 HPV with tumor attributes (including somatic mutations and methylation) and survival. In the 345 present study, we attempted to do this in 153 patients with oral cavity tumors. Supplementary Figure 9 A,B) . Like previous reports 355 [30, 38] , we found p16 expression not to be an effective surrogate marker for HPV detection in oral 356 cavity tumors (there was no tumor that expressed both p16 and had detectable HPV RNA) (Table   357 1). A poor correlation between p16 IHC and HPV in situ hybridization (ISH) is reported in the past 358 [39]. In our study, we did not perform HPV ISH, which could have provided additional information 359 on p16 positivity and HPV prevalence. 360 Unlike antibody-based methods, nucleic acids-based methods detect HPV with high 361 sensitivity and therefore used widely [40] . Meta-analysis of 5478 oral cavity tumors suggested the overall HPV DNA prevalence to be 24.2% with 11% tumors being positive for both HPV DNA and 363 E6/E7 RNA [41] . India has one of the highest incidence rates of oral cavity cancers with a 364 significant difference in the trend of incidence between oropharyngeal and oral cavity cancer [42] . 365 Previously, PCR coupled with MassArray is shown to provide high sensitity of detection with low 366 amount of input genomic DNA [5] . From our results, we found 38% and 13% of the tumors to be 367 positive and negative in all 3 DNA-based assays (PCR, qPCR and ddPCR) respectively. Overall, 368 the prevalence (33-58%) of HPV DNA was dependent on the type of assay used with PCR yielding 369 the highest prevalence over the more sensitive methods like qPCR and ddPCR assays (Table 2A) . 370 This was possibily due to the use of consensus primers in PCR but not in qPCR and ddPCR, in 371 addition to the type-specific ones, resulting in the detection of non-HPV16/18 subtyps. As expected, 372 digital PCR, being the most-sensitive method out of the three DNA-based assays, resulted in more 373 number of tumors being HPV16-DNA positive resulting in the detection of very low copy viral 374 genomes in tumor samples. We wanted to test whether the presence of HPV DNA alone reflects a 375 biological role of HPV in tumors. Based on several levels of evidence as noted below, we conclude 376 that the presence of low copy HPV DNA alone may not be a reflection of functionally active HPV. 377 First, in the tumors positive in HPV DNA, we found only a fraction (15%) with HPV E6/E7 RNA. 378 Second, only 6% of tumors were positive for both the presence of HPV genome and E6/E7 RNA. 379 Third, almost all the tumors with relatively high-copy HPV genome and/or HPV RNA had wild 380 type TP53 and CASP8 genes, which was not the case with tumors with the low-copy HPV DNA. 381 Both TP53 and CASP8 are known to be wild-type primarily in HPV positive tumors [13] and in our 382 study too we found this corresponds to the tumors with high-copy HPV genome and/or 383 transcriptionally active genome only (Table 2B ) . From all of the evidence above, we believe that 384 the presence of HPV DNA in the tumor tissues might have been a result of highly sensitive assays 385 used in our study and might suggest either the presence of passenger HPV genomes coming from 386 adjacent normal cells, as earlier reported [43, 44] and/or be a reflection of inactive or passenger 387 virus in oral cavity tumors. Although very few (n=3), we can not explain why some tumors in our 388 study with HPV E6/E7 RNA did not show the presence of HPV DNA. It is possible that the genomic DNA for those tumors were degraded and therefore, could not serve as ideal templates for 390 DNA-based assays. An additional factor could be the presence of inhibitors for DNA-based assays 391 in those tumors. Although HPV RNA is considered to be gold standard analyte to test for HPV in 392 tumors, RNA is a difficult analyte to handle and is more labile than DNA. Additionally, studying 393 RNA in archival samples may pose additional set of challenges.
394 395 We did not find any significant correlation between p16, HPV-DNA and/or HPV RNA and 396 disease outcome ( Supplementary Figure 9) . Even the tumors with relatively high-copy HPV 397 genomes and/or E6/E7 RNA did not support the role of HPV in patient survival ( Figure 4A ). There 398 are several interesting aspects to our results that need further studies and analysis. First, like 399 cervical tumors [41] but unlike oropharyngeal tumors [13 14 15 16], we did not find HPV to be a 400 predictor of survival. It is possible that HPV has a different mechanism of action in oral cavity 401 tumors. An indirect support to linking high HPV genome copy number with HPV positivity in our 402 study comes from the fact that we did not find significance in HPV-linked genes stratifying HPV 403 +ve from HPV -ve group when HPV DNA irrespective of their copy number is taken into account 404 in defining the HPV positivity ( Figure 4C-D) . It is possible that the presence of high-copy HPV 405 genome in those tumors does not correlate with the presence of biologically active virus. Further 406 studies may help answer this question. Till we have a good answer on high-copy number HPV 407 DNA, HPV RNA may be the best analyte to test for HPV positivity in oral cavity tumors. 
